home / stock / stml / stml news

STML News and Press, Stemline Therapeutics Inc. From 10/08/19

Stock Information
Company Name: Stemline Therapeutics Inc.
Stock Symbol: STML
Market: NASDAQ
Website: stemline.com
Menu
STML STML Quote STML Short STML News STML Articles STML Message Board
Get STML Alerts

News, Short Squeeze, Breakout and More Instantly...
STML - Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS ® (tagraxofusp) clinical data from the pi...
STML - Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data on the felezonexor (SL-801) Phase 1 trial in ...

STML - Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data on felezonexor (SL-801) has been selected...

STML - Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
STML - Stemline Therapeutics: Still A Believer

A cynic is a man who, when he smells flowers, looks around for a coffin .”― H.L. Mencken Today, we revisit a ' Tier 3 ' concern that has seen a fall in its share price despite a spate of good news. This gives investors a nice entry point to establish a new position or add ...

STML - Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...

STML - Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
STML - Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will presen...

STML - Stemline prices stock offering at $15.25

Stemline Therapeutics (NASDAQ: STML ) prices its public offering of 5M common shares at $15.25 per share. Underwriters over-allotment is an additional 750K shares. Closing date is August 13. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read m...

STML - Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public of...
Previous 10 Next 10